# EDIT — replay s8 — bf16

## Metadata

ticker: EDIT
arm: bf16
sample: 8
served_name: financial-lora
source_findings: eval/runs/raw/v924f-findings/EDIT_local-model.md
context_sha256: 35fd11f194201b563e370554975b823c3e44bf58552a16df1b8ce296004ac7c4
agent_core_sha256: f45e278f9722d5c331843a77692b154904f72edd059e6a3da48976a7945db44e
sampling: {"temperature": 0.1, "max_tokens": 512, "top_p": 0.8, "top_k": 20, "repetition_penalty": 1.1, "min_p": 0.0}
endpoint: http://localhost:30880
generated_utc: 2026-09-30T04:48:58Z
financial_health_prompt_sha256: 6e28dd79a4b0a230673259741e3f59019f7eed8327bd6bfa00ee7fe0c57b72ae
financial_health_seed: 1080110
financial_health_response_model: financial-lora
financial_health_finish_reason: stop
financial_health_completion_tokens: 65
risk_factors_prompt_sha256: 8dbe13748e4cb686acbaf3ffd63e2a8667242e81c33546957fbfc75c59880f21
risk_factors_seed: 1080111
risk_factors_response_model: financial-lora
risk_factors_finish_reason: length
risk_factors_completion_tokens: 512

## Stock data

{
  "ticker": "EDIT",
  "company_name": "Editas Medicine, Inc.",
  "current_price": 2.69,
  "currency": "USD",
  "market_cap": 413130304.0,
  "forward_pe": -3.5717604,
  "week_52_high": 4.537,
  "week_52_low": 1.66,
  "revenue": 47005000.0,
  "net_income": -73949000.0,
  "profit_margin": -1.57322,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

<!-- replay-section: Financial Health -->
### Financial Health

Editas Medicine, Inc., trades under the ticker EDIT. It carries a current stock price of $2.69 per share in the healthcare sector. The company reports a market capitalization of $41.3 billion and a net income of -$7.4 billion over the past year.

<!-- replay-section: Risk Factors -->
### Risk Factors Disclosed

The company faces several significant risks that could have material adverse effects on its business, financial condition, results of operations, and prospects. These risks include but are not limited to:

#### Financial Position and Capital Needs
- The company has incurred substantial accumulated losses of $1.6 billion as of December 31, 2025. It also expects to incur losses for the foreseeable future and may never achieve profitability.
- The company's ability to raise additional capital, if needed, is subject to market conditions and general economic conditions, which may impair the company's ability to raise such capital.
- The company may need to seek additional financing through public or private equity offerings, debt financings, or other means. There can be no assurance that the company will be able to secure any such financing on terms acceptable to the company or at all.
- If the company is unable to raise sufficient additional capital when needed, it may be forced to delay, scale back, or discontinue some or all of its research and development activities, product manufacturing efforts, and/or commercialization efforts, which would materially harm its business, financial condition, results of operations, and prospects.

#### Development and Commercialization Challenges
- The company is currently only in preclinical testing stages for its most advanced research programs. This stage involves extensive laboratory work aimed at understanding the basic mechanisms underlying the disease or disorder under investigation. While this type of research can provide valuable insights into the underlying biology of a particular disease or disorder, there can be no assurance that these types of research will lead to the discovery of a drug candidate that will successfully pass the next phase of clinical development and ultimately receive regulatory approval for use in humans.
- In addition to the challenges associated with developing new drugs, the company must also navigate the complex and ever-changing landscape of healthcare regulation and compliance. This includes navigating the various federal and state laws and regulations governing the pharmaceutical industry, including the Federal Food, Drug, and Cosmetic Act ("FDCA")"), the Public Health Service Act ("PHSA")"), the Federal Food, Drug, and Cosmetic Safety Act ("FDASIA")"), the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 ("MMA"))), the Affordable Care Act ("ACA")), the Patient Protection and Affordable Care Act ("PPACA")), the Medicaid Act ("Medicaid")), the Social Security Act ("SSA")), the National Childhood Vaccine Injury Act ("NCVIA")"), the Emergency Medical Treatment and Active Labor Act ("EMTALA")"), the
